RT Journal Article
SR Electronic
T1 The Florida Pancreas Collaborative Next-Generation Biobank: State-wide Infrastructure to Reduce Disparities and Improve Survival for a Racially and Ethnically Diverse Cohort of Patients with Pancreatic Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.10.20209247
DO 10.1101/2020.10.10.20209247
A1 Jennifer B. Permuth
A1 Kaleena B. Dezsi
A1 Shraddha Vyas
A1 Karla N. Ali
A1 Toni L. Basinski
A1 Ovie A. Utuama
A1 Jason W. Denbo
A1 Jason Klapman
A1 Aamir Dam
A1 Estrella Carballido
A1 DaeWon Kim
A1 Jose M. Pimiento
A1 Benjamin D. Powers
A1 Jung W. Choi
A1 Dung-Tsa Chen
A1 Jamie K. Teer
A1 Francisca Beato
A1 Alina Ward
A1 Elena M. Cortizas
A1 Suzanne Y. Whisner
A1 Iverson E. Williams
A1 Andrea N. Riner
A1 Kenneth Tardif
A1 Vic Velanovich
A1 Andreas Karachristos
A1 Wade G. Douglas
A1 Adrian Legaspi
A1 Bassan Allan
A1 Kenneth Meredith
A1 Manual A. Molina-Vega
A1 Philip Bao
A1 Jamii St. Julien
A1 Kevin L. Huguet
A1 B. Lee Green
A1 Folakemi T. Odedina
A1 Nagi B. Kumar
A1 Vani N. Simmons
A1 Thomas J. George
A1 Mokenge Malafa
A1 Pamela Hodul
A1 Juan P. Arnoletti
A1 Ziad T. Awad
A1 Debashish Bose
A1 Kun Jiang
A1 Barbara A. Centeno
A1 Clement K. Gwede
A1 Sarah M. Judge
A1 Andrew R. Judge
A1 Daniel Jeong
A1 Mark Bloomston
A1 Nipun B. Merchant
A1 Jason B. Fleming
A1 Jose G. Trevino
A1 on behalf of the Florida Pancreas Collaborative
YR 2020
UL http://medrxiv.org/content/early/2020/10/13/2020.10.10.20209247.abstract
AB Background Well-annotated, high-quality biorepositories provide a valuable platform to support translational research and discovery. However, most biorepositories have poor representation of minority groups, limiting the ability to address cancer health disparities and improve disease outcomes. This report describes the establishment of the Florida Pancreas Collaborative (FPC), the first state-wide prospective longitudinal cohort study and biorepository specifically designed to address the higher burden of pancreatic cancer (PaCa) in African Americans (AA) compared to Non-Hispanic Whites (NHW) and Hispanic/Latinx (H/L).Methods We describe rationale for establishing the FPC and provide an overview of key stakeholders; study eligibility and design; ascertainment and recruitment strategies; and standard operating procedures (SOPs) developed to collect, process, store, and transfer biospecimens, medical images, and data. We also describe the customized cloud-based, secure data management platform built to facilitate recruitment, track study-related workflow, house data, and perform queries. We also present progress to date regarding recruitment and biobanking.Results The FPC consists of multidisciplinary teams from fifteen Florida medical institutions. From March 2019 through August 2020, 350 patients were assessed for study eligibility, 323 met inclusion/exclusion criteria, and 305 (94%) enrolled, including 228 NHW, 30 AA, and 47 H/L, with 94%, 100%, and 94% participation rates, respectively. A high percentage of participants have donated blood (87%), pancreatic tumor tissue (41%), computed tomography scans (76%), and baseline questionnaire data (62%).Conclusions This biorepository addresses a critical gap in PaCa research with the potential to advance basic, clinical, population-based, and translational studies intended to minimize disparities, increase quality of life, and reduce PaCa-related morbidity and mortality.Impact This multi-institutional infrastructure can serve as a prototype for development of similar resources across the country and disease sites.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research in this publication was supported in part by the James and Esther King Biomedical Research Program, Florida Department of Health (Grant #8JK02; awarded to JPB and JGT), and the Tissue Core, Quantitative Imaging Core, the Participant Research, Interventions, and Measurement (PRISM) Core, the Biostatistics and Bioinformatics Shared Resource, and the Pharmacokinetics and Pharmacodynamics Core at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center (P30-CA076292).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by Advarra IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData for this manuscript is not publicly available. It is protected in a secure database by the lead investigator.